Entrada Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| Research and development | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M |
| Operating expenses | $183.3M | $163.8M | $132.2M | $97.2M | $51.1M |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Income tax expense | $924,000 | $859,000 | $18.7M | $0 | $0 |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M |
| Balance Sheet | |||||
| Cash and equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M |
| Current assets | $306.3M | $440.0M | $369.8M | $209.9M | $298.7M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Current liabilities | $24.5M | $39.5M | $158.8M | $22.0M | $6.7M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
| Stockholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Depreciation and amortization | $4.1M | $3.8M | $2.8M | $1.9M | $1.1M |
| Stock-based compensation | $19.6M | $17.9M | $13.1M | $9.9M | $2.5M |
| Capital expenditure | $1.0M | $3.2M | $5.6M | $2.9M | $4.6M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 38.8M · Free float 41.2%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.